RxDoctor Payments Data

Michael Guo, MD

Internal Medicine · New York, NYNPI 1780649517

Payments from drug & device makers

$3,194in general payments, 2019–2025

Across 34 payments — averaging $93.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$543
  • AbbVie$423
  • Neurocrine Biosciences, Inc.$334
  • Novo Nordisk$250
  • Axsome Therapeutics, Inc.$220
  • Alcon$147
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,182100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,194 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$8,315
Medicare patients
16
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Epolamine247$165,359
FarxigaDapagliflozin Propanediol81$74,805
JardianceEmpagliflozin56$56,789
JanumetSitagliptin Phos/Metformin Hcl43$46,504
JanuviaSitagliptin Phosphate29$39,477
VemlidyTenofovir Alafenamide27$37,532
VascepaIcosapent Ethyl128$36,413
EliquisApixaban37$26,449
TrulicityDulaglutide17$21,241
Combivent RespimatIpratropium/Albuterol Sulfate36$17,688
TradjentaLinagliptin14$16,643
XareltoRivaroxaban18$16,494
Tenofovir Disoproxil Fumarate52$12,572
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,740
BrilintaTicagrelor11$7,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta, Symbicort$125$87,730116 claims
MerckJanumet, Januvia$125$85,98172 claims
GileadVemlidy$543$37,53227 claims
Lilly USA, LLCTrulicity$137$21,24117 claims
Johnson & JohnsonXarelto$90$16,49418 claims
GSKTrelegy Ellipta, Breo Ellipta$135$15,95930 claims
AbbVieCreon$423$6,67816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →